UB-VV200 / Umoja Biopharma - LARVOL DELTA

In vivo-generated TagCAR T cells inhibit solid tumor growth following treatment with bispecific small molecule TumorTags (SITC 2023) - "In response to either PSMA (UB-TT440) or FRa (UB-TT170) targeting TumorTags, TagCAR T cells proliferated and inhibited tumor growth. Conclusions These data demonstrate that, in comparison to autologous CAR T cells, UB-VV200 together with TumorTags have the potential to be a more accessible and more affordable off-the-shelf pan-cancer therapy."

CAR T-Cell Therapy • Preclinical • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor

Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity (GlobeNewswire) - "Umoja Biopharma...announced the presentation of new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting demonstrating potent in vivo CAR T cell generation and robust anti-tumor activity using its VivoVec™ platform....UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with TumorTag™ technology in an in vivo model. Optimization of VivoVec particles increases anti-tumor activity and enables multiple routes of administration for VivoVec-mediated CAR delivery in in vivo models."

Preclinical • Oncology

UB-VV200 is a Novel Surface-Engineered Lentiviral Product Candidate for In Vivo Engineering of Universal TagCAR T Cells for the Treatment of Solid Tumors (ASGCT 2023) - "Overall, we have demonstrated that UB-VV200 can engineer TagCAR T cells in vivo and that UB-TT170 can direct TagCAR T cells to eliminate FRα+ tumor cells. These data support development of UB-VV200 in combination with TumorTags as a new therapeutic approach against solid tumors."

CAR T-Cell Therapy • Preclinical • Hematological Disorders • Hematological Malignancies • Immune Modulation • Oncology • Solid Tumor • FOLR1

Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) - "Umoja Biopharma, Inc...announced today that it will have one oral presentation and one poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, to be held May 16-20, 2023, in Los Angeles."

Preclinical • Oncology • Solid Tumor

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire) - "Umoja Biopharma...announced today new data from three poster presentations at the 2022 Society for Immunotherapy of Cancer 37th Annual Meeting....New preclinical data presented at SITC details the advancement of the VivoVec platform through incorporation of costimulatory molecules into the surface of VivoVec particles....A second poster shared new data supporting the use of the Company’s bispecific small molecule adapters called TumorTags intended to overcome the challenges of eradicating solid tumors that stem from their innate heterogeneity."

Preclinical • Oncology • Solid Tumor